CASE REPORT

CONTROL OF SEVERE BLEEDING EPISODE IN CASE OF GLANZMANN’S THROMBASTHENIA REFRACTORY TO PLATELET TRANSFUSION THERAPY BY ADMINISTERING RECOMBINANT FACTOR VIIa

Asim Javed, Muhammad Ayyub*, Abrar S, Mansoor M, Badshah Khan**, Hussain T**

Combined Military Hospital, *Armed Forces Institute of Transfusion, **Army Medical College, Rawalpindi, Pakistan

Glanzmann’s thrombasthenia is an autosomal recessive inherited platelet function defect. Though, quantitatively normal, the aggregation ability of platelets is reduced leading to bleeding episodes requiring transfusion of platelet concentrates. We describe a case of 13-year-old girl who had recurrent episodes of epistaxis since birth and was managed with multiple platelet concentrate transfusions and recently admitted with severe epistaxis refractory to platelet transfusion. At this stage administration of recombinant activated factor VII (fVIIa) was considered, which was initially given at 90 µg/kg dose with little control of bleeding but subsequent second dose of 120 µg/kg was administered with excellent response and immediate control of bleeding.

**Keywords:** Glanzmann’s thrombasthenia, autosomal recessive, platelet disorder, recombinant factor VIIa, epistaxis

INTRODUCTION

Glanzmann’s thrombasthenia (GT) is a rare disorder of platelet function. The basic pathology in this disease is the quantitative or qualitative deficiency of glycoprotein IIb-IIIa (GP IIb-IIIa) complex, causing inability of platelets to form haemostatic plug. This leads to bleeding episodes. It was described for the first time by Glanzmann in 1918 as ‘hereditary hemorrhagic thrombastyhenia’. A prolonged bleeding time and an isolated, rather than clumped, appearance of platelets on a peripheral blood smear were used as the early diagnostic criteria.1 It is an inherited disorder of platelet function characterised by recurrent bleeding episodes. The laboratory studies show prolonged bleeding time (BT) with a normal platelet count. The global profile of coagulation is normal. Platelet aggregometry shows no response to agonists like Adenosine dinoacotide phosphate (ADP), collagen, and arachidonic acid. The molecular basis of GT is linked to quantitative and/or qualitative abnormalities of αIIbβ3 integrin receptor which mediates the binding of adhesive proteins that attach aggregating platelets and ensure thrombus formation at the sites of injury in blood vessels. Platelet αIIbβ3 deficiency should always be confirmed in new patients, preferably with monoclonal antibodies and flow cytometry.2,3

Clinical presentation in patients with GT is not uniform. Some patients have only minimal bruising while others present with frequent, severe and potentially fatal haemorrhages. The site of bleeding is mucocutaneous with purpura, epistaxis, gingival haemorrhage, and menorrhagia being the most frequent features. Mostly the bleeding symptoms appear early after birth as seen in this case. Occasionally it is diagnosed in later life. The patients are also at an increased risk of severe bleeding during pregnancy and perinatal period. Visceral bleeding in the form of haematomas is usually not a feature of GT. Patients with absent platelet aggregation and no clot retraction have been classified as having type I disease and those with absent aggregation but preserved residual clot retraction as type II disease.4

CASE REPORT

We present a case of 13-year-old girl who was brought to paediatrician at the age of 11 months with history of continuous oozing of blood from her vaccination site. Her physical examination did not reveal any abnormality. Her blood counts showed Hb 6.4 g/dl (hypochromic microcytic) and a platelet count of 334,000/mm3. Bleeding time was more than 15 minutes but rest of the coagulation profile including, prothrombin time and activated partial thromboplastin time were all within normal limits. Platelet aggregation studies were performed which showed no response to agonists like collagen, ADP and adrenaline but exhibited normal platelet aggregation in response to restocetin. Based on platelet function studies a diagnosis of Glanzmann’s thrombasthenia was made.

She had 4 elder siblings who were all healthy. Her parents were first cousins. There was no known history of any bleeding disorder in the family. Since the day of her diagnosis she kept on having spontaneous episodes of mucosal bleeds like epistaxis or gum bleeds and easy bruising, almost every 1–3 months. Mostly the bleeds were minor and managed at home by applying local pressure, and giving anti-fibrinolytic agents but at times hospitalisation was required for platelet transfusion.
Recently she presented to us with persistent epistaxis. Her Hb was 5.1 g/dl, platelet count of 189,000/mm³ and a bleeding time of more than 15 minutes. Nasal packing was done and she was given 24 units of platelet concentrates, 7 units of red cell concentrates and antifibrinolytic agents but her oozing persisted for the next 2 days. At this stage administration of recombinant activated factor VII (rFVIIa, Novo Seven, Novo Nordisk) was considered and initially given at 90 µg/kg dose with little control of bleeding but subsequent second dose of 120 µg/kg was administered with excellent response and immediate control of bleeding. Nasal packing was removed and patient was discharged the next day.

DISCUSSION
This disease is named after Glanzmann who described it for the first time in 1918 as 'hereditary haemorrhagic thrombasthenia'. A prolonged bleeding time and scattered appearance of platelets on peripheral blood smear were the early diagnostic criteria. GT is an inherited disorder of platelet function characterized by bleeding episodes manifesting usually in early life.

A review of 177 patients with GT showed that 102 (58%) of the patients were females and the disease had an increased incidence in populations where marriage among close relatives was common. Despite variations in the severity and frequency of bleeding episodes, most GT patients receive blood transfusions. Local bleeding can be treated by local measures, such as fibrin sealants. Epistaxis and gingival bleeds are successfully controlled in most patients by nasal packing or using antifibrinolytic agents. The fact that most patients receive frequent platelet transfusions resulting in the production of alloantibodies against αIbβ3. Human platelet antigen (HPA)-1 and HPA-3 are localised on GPIIb and GPIIIa, respectively, which are defective in GT, and refractoriness due to alloimmunisation may develop with recurrent platelet transfusions. The development of anti-HPA 1a antibodies in GT patients requires platelet transfusion from donors that lack specific antigen and may result in a variable response to subsequent platelet transfusions. In this case, an acceptable response to platelet transfusions was demonstrated in the previous bleeding episodes because the bleeding time always became normal and bleeding stopped, however repeated platelet transfusions administered in the last episode were not effective to stop bleeding likely due to development of anti-HPA 1a antibodies.

The treatment of GT is a challenging issue, especially when repeated platelet transfusions have induced anti-GPIIb/IIIa antibodies. Antibodies have been successfully removed prior to surgery by immunoadsorption on Protein A Sepharose. Plasmapharesis followed by platelet transfusions have been successfully used for prevention and treatment of intra and postpartum bleeding in cases of Glanzmann’s disease. These are complex procedures and their use is limited to specialized centres. In few patients, the condition has been thought to be sufficiently serious to consider allogeneic bone-marrow transplantation. Recombinant factor VIIa (rFVIIa) (NovoSeven) has been successfully used in cases of platelet functions defect and represents an alternative approach for early cessation of bleeding, especially for patients with antibodies and/or a history of refractoriness to transfusion. It is often used in combination with anti-fibrinolytic agents. The drug is still fairly expensive, making it a difficult choice in developing countries.

The exact mechanism of action of recombinant factor VIIa in achieving haemostasis in GT is not fully understood. FXIIa plays a key role in the initiation of haemostasis. In fact, according to a cell-based model of coagulation following injury to the vessel wall, tissue factor (TF) is exposed to circulating blood and TF-FVIIa complexes are formed on the TF-bearing cells, where they activate factor X (FXa), leading to the conversion of prothrombin to thrombin. The limited amount of thrombin formed subsequently activates the co-factors V, VIII and XI, as well as platelets accumulated at the site of injury. The activated platelets expose negatively charged phospholipids, such as phosphatidyl serine on their membrane and FIXa, FVIIIa, and FXa bind to this surface leading to further FX activation and full thrombin generation. The most important observation in this case report is that rFVIIa was not effective at low dose 90 µg/kg but excellent response was observed with dose escalation to 120 µg/kg. Further studies are needed to elucidate the mechanism resulting in activation of platelets at higher doses of rFVIIa.

REFERENCES


Address for Correspondence
Professor Muhammad Ayyub, Director, Armed Forces Institute of Transfusion, Rawalpindi, Pakistan. Tel: +92-51-5527565
Email: afitrwp@yahoo.com